EXAS vs. DXCM

Last updated Jun 4, 2026

EXAS (Exact Sciences Corporation) and DXCM (DexCom, Inc.) are both stocks. Both operate in the Diagnostics & Research industry within the Healthcare sector. At a 0.28 correlation, their price movements are largely independent.

Performance

EXAS vs. DXCM - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Exact Sciences Corporation (EXAS) and DexCom, Inc. (DXCM). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

EXAS

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

DXCM

• 1D: -0.93%
• 1M: 21.20%
• YTD: 9.64%
• 6M: 12.21%
• 1Y: -16.15%
• 3Y*: -15.95%
• 5Y*: -5.34%
• 10Y*: 15.73%

*Multi-year figures are annualized to reflect compound growth (CAGR)

EXAS vs. DXCM - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
EXAS Exact Sciences Corporation	3.30%	80.74%	-24.05%	49.42%	-36.39%	-41.26%	43.26%	46.56%	20.10%	293.26%
DXCM DexCom, Inc.	9.64%	-14.66%	-37.33%	9.58%	-15.64%	45.23%	69.02%	82.59%	108.75%	-3.87%

Correlation

The correlation between EXAS and DXCM is 0.16, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.16
Correlation (3Y) Calculated over the trailing 3-year period	0.25
Correlation (5Y) Calculated over the trailing 5-year period	0.37
Correlation (10Y) Calculated over the trailing 10-year period	0.38
Correlation (All Time) Calculated using the full available price history since Apr 15, 2005	0.28

The correlation between EXAS and DXCM shifts across timeframes, from 0.16 (1 year) to 0.38 (10 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap EXAS : $19.91B DXCM : $28.64B
EPS EXAS : -$1.10 DXCM : $2.31
PS Ratio EXAS : 6.12 DXCM : 6.07
PB Ratio EXAS : 8.29 DXCM : 9.69
Total Revenue (TTM) EXAS : $3.25B DXCM : $4.82B
Gross Profit (TTM) EXAS : $2.26B DXCM : $2.96B
EBITDA (TTM) EXAS : $42.61M DXCM : $1.37B

Return for Risk

EXAS vs. DXCM — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

DXCM

DXCM Risk / Return Rank: 24
DXCM Sharpe Ratio Rank: 23
DXCM Sortino Ratio Rank: 23
DXCM Omega Ratio Rank: 22
DXCM Calmar Ratio Rank: 26
DXCM Martin Ratio Rank: 27

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

EXAS vs. DXCM - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Exact Sciences Corporation (EXAS) and DexCom, Inc. (DXCM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	EXAS	DXCM	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	-0.40	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	-0.11	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.33	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	0.30	—

Drawdowns

Drawdown Indicators

	EXAS	DXCM	Difference
Max Drawdown Largest peak-to-trough decline	—	-94.61%	—
Max Drawdown (1Y) Largest decline over 1 year	—	-38.75%	—
Max Drawdown (3Y) Largest decline over 3 years	—	-60.95%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-66.32%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-66.32%	—
Current Drawdown Current decline from peak	—	-55.31%	—
Average Drawdown Average peak-to-trough decline	—	-35.99%	—
Ulcer Index Depth and duration of drawdowns from previous peaks	—	22.63%	—

Volatility

Volatility by Period

	EXAS	DXCM	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	13.22%	—
Volatility (6M) Calculated over the trailing 6-month period	—	24.61%	—
Volatility (1Y) Calculated over the trailing 1-year period	—	40.26%	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	—	46.91%	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	—	48.43%	—

Dividends

EXAS vs. DXCM - Dividend Comparison

Neither EXAS nor DXCM has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

EXAS vs. DXCM - Profitability Comparison

The chart below illustrates the profitability comparison between Exact Sciences Corporation and DexCom, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

EXAS - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Exact Sciences Corporation reported a gross profit of 615.83M and revenue of 878.38M. Therefore, the gross margin over that period was 70.1%.

DXCM - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, DexCom, Inc. reported a gross profit of 750.30M and revenue of 1.19B. Therefore, the gross margin over that period was 63.0%.

EXAS - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Exact Sciences Corporation reported an operating income of -76.68M and revenue of 878.38M, resulting in an operating margin of -8.7%.

DXCM - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, DexCom, Inc. reported an operating income of 255.30M and revenue of 1.19B, resulting in an operating margin of 21.4%.

EXAS - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Exact Sciences Corporation reported a net income of -85.96M and revenue of 878.38M, resulting in a net margin of -9.8%.

DXCM - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, DexCom, Inc. reported a net income of 199.50M and revenue of 1.19B, resulting in a net margin of 16.7%.

Frequently Asked Questions

Can I hold both EXAS and DXCM in my portfolio?

EXAS and DXCM have a correlation of 0.16, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.